Loading stock data…
$5.75+0.03 (+0.52%)
Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. in the Healthcare sector is trading at $5.75 with a market capitalization of $361M. Wall Street consensus targets $12.43 (7 analysts), implying a +116.1% move over the next 12 months. The stock is currently 12% below its 52-week high of $6.50, remaining 28.9% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $88,000↓ | $110,000↓ | $30.92M↑ | $861,000↑ | $836,000 |
| Gross Profit | $63,000↓ | $78,000↓ | $30.87M↑ | $812,000↑ | $790,000 |
| Operating Income | -$22.36M↓ | -$22.08M↓ | $6.75M↑ | -$20.31M↓ | -$19.33M |
| Net Income | -$23.75M↓ | -$20.69M↓ | $6.25M↑ | -$20.83M↓ | -$19.36M |
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, a...